<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087877</url>
  </required_header>
  <id_info>
    <org_study_id>PTL902020</org_study_id>
    <nct_id>NCT03087877</nct_id>
  </id_info>
  <brief_title>Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor</brief_title>
  <official_title>Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DexCom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to demonstrate effectiveness of the G6 sensor membrane, in
      preventing acetaminophen's interference effect on glucose sensing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The interference effect of the sensor will be evaluated by comparing the bias in the glucose
      values exhibited from the G6 CGM system after administration of acetaminophen. Bias will be
      evaluated by comparing CGM values to a laboratory referenceusing venous sample measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2017</start_date>
  <completion_date type="Actual">March 4, 2017</completion_date>
  <primary_completion_date type="Actual">March 4, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The system will be blinded to the user, i.e. no glucose values will be displayed to the subject during the study duration.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Interference Effect for the G6 CGM</measure>
    <time_frame>6 hrs post dose</time_frame>
    <description>Bias of sensor to reference measurement pre and post acetaminophen administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean of sensor minus YSI values (bias) for various time periods</measure>
    <time_frame>6 hrs post dose</time_frame>
    <description>Bias calculated for pre-dose, post dose and peak post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of interference effect for the G6 CGM</measure>
    <time_frame>6 hrs post dose</time_frame>
    <description>Length of time the inhibition effect is more than 10 mg/dL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CGM Users</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acetaminophen Challenge (G6 CGM)</intervention_name>
    <description>Evaluation of acetaminophen effect on CGM glucose sensing</description>
    <arm_group_label>CGM Users</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 or older

          -  Diagnosis of diabetes

        Exclusion Criteria:

          -  Pregnancy

          -  Known gastroparesis

          -  Abnormal liver function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Price, MD</last_name>
    <role>Study Director</role>
    <affiliation>DexCom, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMCR</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Sansum Diabetes Center</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center Inc</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>December 27, 2018</last_update_submitted>
  <last_update_submitted_qc>December 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

